{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:49:15Z","timestamp":1788580155715,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-023-02612-w","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T12:02:59Z","timestamp":1690459379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Flexible New Dosage Forms Containing Carvedilol for the Treatment of Patients with Cardiovascular Disorders: Development, Stability, Palatability, and Microbiological Studies"],"prefix":"10.1208","volume":"24","author":[{"given":"Mar\u00eda Alejandra","family":"Operto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-3570","authenticated-orcid":false,"given":"Dar\u00edo","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Vignaduzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"2612_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1542\/peds.2013-32251","volume":"134","author":"V Ivanovska","year":"2014","unstructured":"Ivanovska V, Rademaker CMA, van Dijk L, Mantel-Teeuwisse AK. Pediatric drug formulations: a review of challenges and progress. Pediatrics. 2014;134:361\u201372. https:\/\/doi.org\/10.1542\/peds.2013-32251.","journal-title":"Pediatrics."},{"key":"2612_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.maturitas.2019.03.0071","volume":"124","author":"L Mieiro","year":"2019","unstructured":"Mieiro L, Beuscart J-B, Knol W, Van Riet-Nales D, Orlu M. Achieving appropriate medication for older adults: a multidimensional perspective. Maturitas. 2019;124:43\u20137. https:\/\/doi.org\/10.1016\/j.maturitas.2019.03.0071.","journal-title":"Maturitas."},{"key":"2612_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.6051\/j.issn.2224-3992.2014.03.408-21","volume":"3","author":"M Walshe","year":"2014","unstructured":"Walshe M. Oropharyngeal dysphagia in neurodegenerative disease. J Gastroenterol Hepatol Res. 2014;3:1265\u201371. https:\/\/doi.org\/10.6051\/j.issn.2224-3992.2014.03.408-21.","journal-title":"J Gastroenterol Hepatol Res."},{"key":"2612_CR4","first-page":"512","volume":"9.1","author":"SM Hanning","year":"2016","unstructured":"Hanning SM, Lopez FL, Wong ICK, Ernest TB, Tuleu COGM. Patient centric formulations for paediatrics and geriatrics: similarities and differences. Int J Pharm. 2016;9.1:512\u2013355.","journal-title":"Int J Pharm."},{"key":"2612_CR5","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1517\/17425247.2015.10602181","volume":"12","author":"FL Lopez","year":"2015","unstructured":"Lopez FL, Ernest TB, Tuleu C, Gul MO. Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. Exp Opin Drug Deliv. 2015;12:1727\u201340. https:\/\/doi.org\/10.1517\/17425247.2015.10602181.","journal-title":"Exp Opin Drug Deliv."},{"key":"2612_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jpba.2008.05.0041","volume":"48","author":"O Galanopoulou","year":"2008","unstructured":"Galanopoulou O, Rozou S, Antoniadou-Vyza E. HPLC analysis, isolation and identification of a new degradation product in carvedilol tablets. J Pharma Biomed Anal. 2008;48:70\u20137. https:\/\/doi.org\/10.1016\/j.jpba.2008.05.0041.","journal-title":"J Pharma Biomed Anal."},{"key":"2612_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1208\/s12249-008-9055-71","volume":"9","author":"T Loftsson","year":"2008","unstructured":"Loftsson T, Vogensen SB, Desbos C, Jansook P. Carvedilol: solubilization and cyclodextrin complexation: a technical note. AAPS PharmSciTech. 2008;9:425\u201330. https:\/\/doi.org\/10.1208\/s12249-008-9055-71.","journal-title":"AAPS PharmSciTech."},{"key":"2612_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.pedneo.2017.01.0011","volume":"58","author":"D Masarone","year":"2017","unstructured":"Masarone D, Valente F, Rubino M, et al. Pediatric heart failure: a practical guide to diagnosis and management. Pediatr Neonatol. 2017;58:303\u201312. https:\/\/doi.org\/10.1016\/j.pedneo.2017.01.0011.","journal-title":"Pediatr Neonatol."},{"key":"2612_CR9","unstructured":"FDA Listing of Authorized Generics 2022. Available at https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/fda-listing-authorized-generics1."},{"key":"2612_CR10","unstructured":"Carvedilol. Available at https:\/\/medlineplus.gov\/spanish\/druginfo\/meds\/a697042-es.html1."},{"key":"2612_CR11","first-page":"392","volume":"6","author":"TV Menon","year":"2013","unstructured":"Menon TV, Sajeeth CL. Formulation and evaluation of sustained release sodium alginate microbeads of Carvedilol. J Pharm Technol. 2013;6:392\u2013397.1.","journal-title":"J Pharm Technol."},{"key":"2612_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejps.2017.02.0061","volume":"101","author":"M Krsti\u0107","year":"2017","unstructured":"Krsti\u0107 M, Radojevi\u0107 M, Stojanovi\u0107 D, Radojevi\u0107 V, Uskokovi\u0107 P, Ibri\u0107 S. Formulation and characterization of nanofibers and films with carvedilol prepared by electrospinning and solution casting method. Eur J Pharm Sci. 2017;101:160\u20136. https:\/\/doi.org\/10.1016\/j.ejps.2017.02.0061.","journal-title":"Eur J Pharm Sci."},{"key":"2612_CR13","doi-asserted-by":"publisher","first-page":"102199","DOI":"10.1016\/j.nano.2020.1021991","volume":"27","author":"H Han","year":"2020","unstructured":"Han H, Li Y, Peng Z, et al. A Soluplus\/Poloxamer 407-based self-nanoemulsifying drug delivery system for the weakly basic drug carvedilol to improve its bioavailability. Nanomed Nanotechnol Biol Med. 2020;27:102199. https:\/\/doi.org\/10.1016\/j.nano.2020.1021991.","journal-title":"Nanomed Nanotechnol Biol Med."},{"key":"2612_CR14","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3109\/10717544.2016.11653141","volume":"23","author":"A Mishra","year":"2016","unstructured":"Mishra A, Imam SS, Aqil M, et al. Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation. Drug Deliv. 2016;23:1486\u201394. https:\/\/doi.org\/10.3109\/10717544.2016.11653141.","journal-title":"Drug Deliv."},{"key":"2612_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/jphp.126051","volume":"69","author":"M Wegmann","year":"2017","unstructured":"Wegmann M, Parola L, Bertera FM, et al. Novel carvedilol paediatric nanomicelle formulation: in-vitro characterization and in-vivo evaluation. J Pharm Pharmacol. 2017;69:544\u201353. https:\/\/doi.org\/10.1111\/jphp.126051.","journal-title":"J Pharm Pharmacol."},{"key":"2612_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijpharm.2018.02.0111","volume":"540","author":"D Medarevi\u0107","year":"2018","unstructured":"Medarevi\u0107 D, Djuri\u0161 J, Ibri\u0107 S, Mitri\u0107 M, Kachrimanis K. Optimization of formulation and process parameters for the production of carvedilol nanosuspension by wet media milling. Int J Pharm. 2018;540:150\u201361. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.02.0111.","journal-title":"Int J Pharm."},{"key":"2612_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.farma.2010.01.002","volume":"34","author":"F Buontempo","year":"2010","unstructured":"Buontempo F, Bernabeu E, Glisoni RJ, Quiroga E, DA BCC. Carvedilol stability in paediatric oral liquid formulations. Farmacia Hospitalaria. 2010;34:293\u20137.1.","journal-title":"Farmacia Hospitalaria"},{"key":"2612_CR18","unstructured":"(ICH) INTERNATIONAL CONFERENCE ON HARMONISATION. Validation of analytical procedures Q2(R2), in: 2022.1. https:\/\/www.ema.europa.eu\/en\/ich-q2r2-validation-analytical-procedures-scientific-guideline"},{"key":"2612_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/jppr.11271","volume":"46","author":"RP Patel","year":"2016","unstructured":"Patel RP, Wanandy T, Zani R, Jose MD, Shastri M, Zaidi STR. Stability of trimethoprim in newly formulated liquid dosage form. J Pharm Pract Res. 2016;46:10\u20134. https:\/\/doi.org\/10.1002\/jppr.11271.","journal-title":"J Pharm Pract Res."},{"key":"2612_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jppr.16121","volume":"50","author":"DP Ellis","year":"2020","unstructured":"Ellis DP, Rozek T, Milne RW. Stability of a compounded oral liquid formulation of clopidogrel for infants. J Pharm Pract Res. 2020;50:321\u20138. https:\/\/doi.org\/10.1002\/jppr.16121.","journal-title":"J Pharm Pract Res."},{"key":"2612_CR21","unstructured":"European Pharmacopoeia. European Directorate for the Quality of Medicines EDQM, seventh ed. Strasbourg; 2010. pp. 163\u2013167, 519\u2013520."},{"key":"2612_CR22","doi-asserted-by":"publisher","unstructured":"Morri M, Casabonne C, Leonardi D., Vignaduzzo S. Orphan formulations for pediatric use: development and stability control of two sildenafil citrate solutions for the treatment of pulmonary hypertension. AAPS Pharmscitech. 2020:21. https:\/\/doi.org\/10.1208\/s12249-020-01768-z1.","DOI":"10.1208\/s12249-020-01768-z1"},{"key":"2612_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1208\/s12249-015-0365-21","volume":"17","author":"R Hamed","year":"2016","unstructured":"Hamed R, Awadallah A, Sunoqrot S, et al. pH-dependent solubility and dissolution behavior of carvedilol\u2014case example of a weakly basic BCS class II drug. AAPS PharmSciTech. 2016;17:418\u201326. https:\/\/doi.org\/10.1208\/s12249-015-0365-21.","journal-title":"AAPS PharmSciTech."},{"key":"2612_CR24","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/tmi.129801","volume":"22","author":"HF Santos Souza","year":"2017","unstructured":"Santos Souza HF, Real D, Leonardi D, et al. Development and in vitro\/in vivo evaluation of a novel benznidazole liquid dosage form using a quality-by-design approach. TM & IH. 2017;22:1514\u201322. https:\/\/doi.org\/10.1111\/tmi.129801.","journal-title":"TM & IH."},{"key":"2612_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ijpharm.2013.11.0061","volume":"460","author":"N Provenza","year":"2014","unstructured":"Provenza N, Calpena AC, Mallandrich M, Halbaut L, Clares B. Design and physicochemical stability studies of paediatric oral formulations of sildenafil. Int J Pharm. 2014;460:234\u20139. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.11.0061.","journal-title":"Int J Pharm."},{"key":"2612_CR26","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1208\/s12249-018-0992-51","volume":"19","author":"M Morri","year":"2018","unstructured":"Morri M, Castellano P, Leonardi D, Vignaduzzo S. First development, optimization, and stability control of a pediatric oral atenolol formulation. AAPS PharmSciTech. 2018;19:1781\u20138. https:\/\/doi.org\/10.1208\/s12249-018-0992-51.","journal-title":"AAPS PharmSciTech."},{"key":"2612_CR27","unstructured":"Plummer DT. Introducci\u00f3n a la bioqu\u00edmica pr\u00e1ctica (No. 574.192 P5Y 1981). 1981. https:\/\/books.google.com.co\/books?id=LFzyWzsCVlsC&printsec=frontcover#v=onepage&q&f=false"},{"key":"2612_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejps.2017.01.0251","volume":"100","author":"AC van der Vossen","year":"2017","unstructured":"van der Vossen AC, van der Velde I, Smeets OSNM, et al. Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug. Eur J Pharm Sci. 2017;100:205\u201310. https:\/\/doi.org\/10.1016\/j.ejps.2017.01.0251.","journal-title":"Eur J Pharm Sci."},{"key":"2612_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","volume":"21","author":"RG Strickley","year":"2004","unstructured":"Strickley RG. Solubilizing excipients used in commercially available oral and injectable formulations. Pharm Res. 2004;21:201\u2013230.1.","journal-title":"Pharm Res."},{"key":"2612_CR30","unstructured":"(ICH) INTERNATIONAL CONFERENCE ON HARMONISATION, Q1A (R2) Stability testing of new drug substances and drug products In:2003. Available at https:\/\/www.ema.europa.eu\/en\/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline%0A1."},{"key":"2612_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0378-5173(00)00610-41","volume":"212","author":"S Raghavan","year":"2001","unstructured":"Raghavan S, Trividic A, Davis A, Hadgraft J. Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm. 2001;212:213\u201321. https:\/\/doi.org\/10.1016\/S0378-5173(00)00610-41.","journal-title":"Int J Pharm."},{"key":"2612_CR32","unstructured":"(ICH) INTERNATIONAL CONFERENCE ON HARMONISATION. Evaluation for Stability Data Q1E, 2003. https:\/\/database.ich.org\/sites\/default\/files\/Q1EGuideline.pdf."},{"key":"2612_CR33","unstructured":"European Medicines Agency. Reflection paper: formulation of choice for the paediatric population (EMEA\/CHMP\/PEG\/194810\/2005). Eur Med Agency. EMEA\/CHMP\/:1\u201345.1. 2006. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-formulations-choice-paediatricpopulation_en.pdf"},{"key":"2612_CR34","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jamda.2017.02.0151","volume":"18","author":"O Ortega","year":"2017","unstructured":"Ortega O, Mart\u00edn A, Clav\u00e9 P. Diagnosis and management of oropharyngeal dysphagia among older persons, state of the art. J Am Med Dir Assoc. 2017;18:576\u201382. https:\/\/doi.org\/10.1016\/j.jamda.2017.02.0151.","journal-title":"J Am Med Dir Assoc."},{"key":"2612_CR35","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00467-019-04314-71","volume":"35","author":"N Siddiqi","year":"2020","unstructured":"Siddiqi N, Shatat IF. Antihypertensive agents: a long way to safe drug prescribing in children. Pediatric Nephrol. 2020;35:2049\u201365. https:\/\/doi.org\/10.1007\/s00467-019-04314-71.","journal-title":"Pediatric Nephrol."},{"key":"2612_CR36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0167-4943(99)00040-01","volume":"29","author":"R Leonetti Luparini","year":"2000","unstructured":"Leonetti Luparini R, Celli V, Piccirillo G, Guidi V, Cacciafesta M, Marigliano V. Carvedilol in elderly patients with chronic heart failure, a 12 weeks randomized, placebo controlled open trial. Arch Gerontol Geriatr. 2000;29:275\u201382. https:\/\/doi.org\/10.1016\/S0167-4943(99)00040-01.","journal-title":"Arch Gerontol Geriatr."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-023-02612-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-023-02612-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-023-02612-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:13:21Z","timestamp":1692710001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-023-02612-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2612"],"URL":"https:\/\/doi.org\/10.1208\/s12249-023-02612-w","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"8 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no declarations of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"159"}}